Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AnaptysBio, Inc. (ANAB : NSDQ)

• Company Description    AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. Number of Employees: 136

• Price / Volume Information    Yesterday's Closing Price: $39.65 Daily Weekly Monthly 20 Day Moving Average: 372,676 shares Shares Outstanding: 27.69 (millions) Market Capitalization: $1,097.85 (millions) Beta: 0.16 52 Week High: $40.96 52 Week Low: $12.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.40% 23.08% 12 Week 96.87% 88.71% Year To Date 199.47% 161.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10770 WATERIDGE CIRCLE SUITE 210 - SAN DIEGO,CA 92121 USA ph: 858-362-6295 fax: - investors@anaptysbio.com http://www.anaptysbio.com

• General Corporate Information    Officers Daniel Faga - President; Chief Executive Officer and Director Dennis Mulroy - Chief Financial Officer Dennis Fenton - Director Rita Jain - Director Oleg Nodelman - Director Peer Information AnaptysBio, Inc. (CORR.) AnaptysBio, Inc. (RSPI) AnaptysBio, Inc. (CGXP) AnaptysBio, Inc. (BGEN) AnaptysBio, Inc. (GTBP) AnaptysBio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 032724106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 27.69 Most Recent Split Date: (:1) Beta: 0.16 Market Capitalization: $1,097.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.99 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 6.48 EPS Growth vs. Year Ago Period: 145.61% vs. Previous Quarter: 138.81% Sales Growth vs. Year Ago Period: 154.26% vs. Previous Quarter: 242.81% ROE 09/30/25 - -1,101.24 06/30/25 - -366.98 03/31/25 - -282.47 ROA 09/30/25 - -21.23 06/30/25 - -30.58 03/31/25 - -30.79 Current Ratio 09/30/25 - 8.68 06/30/25 - 8.22 03/31/25 - 8.25 Quick Ratio 09/30/25 - 8.68 06/30/25 - 8.22 03/31/25 - 8.25 Operating Margin 09/30/25 - -49.94 06/30/25 - -107.66 03/31/25 - -125.70 Net Margin 09/30/25 - -49.94 06/30/25 - -107.66 03/31/25 - -125.70 Pre-Tax Margin 09/30/25 - -49.89 06/30/25 - -107.59 03/31/25 - -125.66 Book Value 09/30/25 - -1.06 06/30/25 - -1.52 03/31/25 - 1.15 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00

Powered by Zacks Investment Research ©